Kiora Pharmaceuticals Operating Margin vs. Net Income

KPRX Stock  USD 1.96  0.02  1.01%   
Based on Kiora Pharmaceuticals' profitability indicators, Kiora Pharmaceuticals is yielding more profit at this time then in previous quarter. It has a moderate odds of reporting better profitability numbers in March. Profitability indicators assess Kiora Pharmaceuticals' ability to earn profits and add value for shareholders.

Kiora Pharmaceuticals Operating Profit Margin

0.34

Operating Cash Flow Sales Ratio is likely to rise to 0.65 in 2026, whereas Price To Sales Ratio is likely to drop 0.68 in 2026. At this time, Kiora Pharmaceuticals' Income Quality is fairly stable compared to the past year. Net Income Per E B T is likely to rise to 1.08 in 2026, despite the fact that Accumulated Other Comprehensive Income is likely to grow to (241.2 K). At this time, Kiora Pharmaceuticals' Gross Profit is fairly stable compared to the past year. Pretax Profit Margin is likely to rise to 0.43 in 2026, despite the fact that Gross Profit Margin is likely to grow to (295.40).
For Kiora Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kiora Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kiora Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kiora Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kiora Pharmaceuticals over time as well as its relative position and ranking within its peers.
Check out Correlation Analysis.
For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.By analyzing Kiora Pharmaceuticals' earnings estimates, investors can diagnose different trends across Kiora Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Kiora Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
 
Interest Hikes
Kiora Pharmaceuticals is projected to generate -0.5975 in earnings per share on the 31st of December 2025. Kiora Pharmaceuticals earnings estimates show analyst consensus about projected Kiora Pharmaceuticals EPS (Earning Per Share). It derives the highest and the lowest estimates based on Kiora Pharmaceuticals' historical volatility. Many public companies, such as Kiora Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Kiora Pharmaceuticals' earnings estimates, investors can diagnose different trends across Kiora Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. Expected growth trajectory for Kiora significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kiora Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(2.19)
Return On Assets
(0.17)
Return On Equity
(0.33)
Understanding Kiora Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Kiora's accounting equity. The concept of intrinsic value - what Kiora Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Kiora Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Kiora Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kiora Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Kiora Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.

Kiora Pharmaceuticals Net Income vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Kiora Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kiora Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Kiora Pharmaceuticals is currently under evaluation in operating margin category among its peers. It is currently regarded as number one stock in net income category among its peers . At this time, Kiora Pharmaceuticals' Operating Profit Margin is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kiora Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Kiora Net Income vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Kiora Pharmaceuticals

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
null
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Kiora Pharmaceuticals

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
3.59 M
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

Kiora Net Income Comparison

Kiora Pharmaceuticals is currently under evaluation in net income category among its peers.

Kiora Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Kiora Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kiora Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Kiora Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Kiora Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-253.9 K-241.2 K
Operating Income4.1 M4.3 M
Income Before Tax5.1 M5.3 M
Total Other Income Expense Net1.3 M1.4 M
Net Income3.2 M3.4 M
Income Tax Expense1.9 MM
Net Interest Income1.4 M1.5 M
Interest Income1.4 M1.5 M
Net Income From Continuing Ops4.1 M4.3 M
Net Loss-14.8 M-15.5 M
Change To Netincome7.3 M7.6 M
Net Income Per Share 0.84  0.88 
Income Quality 2.14  2.25 
Net Income Per E B T 0.73  1.08 

Kiora Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Kiora Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kiora Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kiora Pharmaceuticals' important profitability drivers and their relationship over time.

Kiora Pharmaceuticals Earnings per Share Projection vs Actual

Use Kiora Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kiora Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiora Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Kiora Pharmaceuticals Pair Trading

Kiora Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Kiora Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kiora Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kiora Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kiora Pharmaceuticals to buy it.
The correlation of Kiora Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kiora Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kiora Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kiora Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Kiora Pharmaceuticals position

In addition to having Kiora Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Top Crypto Assets Thematic Idea Now

Top Crypto Assets
Top Crypto Assets Theme
An experimental p2p digital currency that is accepted by many vendors in null. The Top Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Top Crypto Assets Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.